Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02669771 | Long-Term Specified Drug Use-Results Survey for Xtandi Capsule | completed | — | 1,018 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02787005 | Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) | completed | Phase 2 | 388 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 21, 2024 | clinicaltrials |
| NCT03328364 | A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | completed | — | 211 | Astellas Pharma a/sINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05381311 | Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study | completed | — | 1,020 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02380274 | Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)(TRUMPET) | completed | — | 1,030 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03248570 | Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | completed | Phase 2 | 26 | University of California, San FranciscoOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04094519 | A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer | completed | Phase 1 | 24 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06362291 | Comparison of MRI AI-cTB Versus Routine cTB in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial | completed | N/A | 380 | Peking University First HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03535987 | Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy | completed | — | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05064670 | Exercise as Medicine for People With Cancer Sweden(EX-MED) | completed | N/A | 200 | Karolinska InstitutetOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02213107 | Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. | completed | Phase 2 | 43 | University of RochesterOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03414034 | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01325506 | Effectiveness of Open and Robotic Prostatectomy(PROSTQA-RP2) | completed | — | 677 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03128710 | Prostate Cancer Survey | completed | — | 224 | University of Maryland, BaltimoreOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05715827 | A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System | completed | — | 42 | Medtronic - MITGINDUSTRY | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05895279 | Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III Study(MiCaP) | completed | N/A | 220 | Mayo ClinicOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05498623 | MR Fingerprinting for Diagnostic of Prostate Cancer | completed | — | 203 | Norwegian University of Science and TechnologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05759273 | A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy(REAL6T) | completed | — | 167 | IpsenINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT01964170 | A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer | completed | Phase 3 | 234 | Astellas Pharma IncINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03776968 | A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics | completed | Phase 1 | 47 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04978675 | An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06566989 | A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) | completed | Phase 1 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02495974 | European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)(PREMISE) | completed | — | 1,763 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Oct 21, 2024 | clinicaltrials |
| NCT04583072 | Stockholm3 Validation Study in a Multi-Ethnic Cohort(SEPTA) | completed | — | 2,152 | Karolinska InstitutetOTHER | 2 | Oct 21, 2024 | clinicaltrials |
| NCT05959564 | A Chatbot Intervention for Reducing HPV Vaccine Hesitancy | completed | N/A | 456 | University of Maryland, College ParkOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03507725 | Early Staged Consent Before Prostate Biopsy | completed | N/A | 390 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05655715 | Checkpoint Inhibitors and SBRT for MCRPC(CheckPRO) | completed | Phase 2 | 90 | Herlev and Gentofte HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03204812 | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04605276 | Threedimensional Multiparametric Ultrasound for Prostate Cancer Detection(3DmpUS for PCa) | completed | — | 608 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02555397 | Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer | completed | Phase 1 | 15 | Henry Ford Health SystemOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04060394 | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | completed | Phase 1 / Phase 2 | 49 | Laekna LimitedINDUSTRY | 2 | Oct 10, 2024 | clinicaltrials |
| NCT00207649 | Shared Decision Making: Prostate Cancer Screening | completed | N/A | 641 | Lisa RicharsonFED | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer(ProVent) | completed | Phase 3 | 532 | DendreonINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT01985828 | CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer | completed | N/A | 83 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03489057 | Efficacy of a Couple-Focused mHealth Symptom Self-management Program | completed | N/A | 560 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT01774071 | Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT05181800 | FIRMAGON® Intensive Drug Monitoring | completed | — | 1,454 | Ferring PharmaceuticalsINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02783950 | Genomics in Michigan Impacting Observation or Radiation(G-MINOR) | completed | N/A | 356 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT04207255 | Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | completed | Phase 2 | 69 | Medical University of South CarolinaOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT00365105 | Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer | completed | Phase 3 | 261 | Radiation Therapy Oncology GroupNETWORK | 1 | Sep 20, 2024 | clinicaltrials |
| NCT00580476 | Assessing Depression in a Geriatric Cancer Population | completed | — | 201 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02099864 | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | completed | Phase 2 | 36 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03558711 | PSMA-PET/CT for Prostate Cancer(NGP1) | completed | Phase 1 | 6 | University Hospital, GhentOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03585660 | Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy | completed | N/A | 106 | University of ChicagoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04733768 | 18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer | completed | Phase 2 | 100 | University of AlbertaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04852224 | Strength, Aging, and Memory in Prostate Cancer(STAMP) | completed | — | 20 | University of NebraskaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05318131 | Sleep, Exercise, Nutrition and Survivorship in Prostate Cancer | completed | N/A | 50 | NYU Langone HealthOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2024source: clinicaltrials